BioNTech to present first quarter results
The German vaccine manufacturer BioNTech will on Monday present its results for the first quarter of 2021. In the past months the global demand for the COVID-19 vaccine produced by BioNTech with its U.S. partner Pfizer have transformed the firm’s financial figures. In the fourth quarter, BioNTech booked a net profit of 366.9 million euros […]
The German vaccine manufacturer BioNTech will on Monday present its results for the first quarter of 2021.
In the past months the global demand for the COVID-19 vaccine produced by BioNTech with its U.S. partner Pfizer have transformed the firm’s financial figures.
In the fourth quarter, BioNTech booked a net profit of 366.9 million euros (446.2 million dollars), compared to a net loss of 58.2 million euros during the same quarter of the previous year.
But recent concerns about possibly losing patent rights have caused a stir among shareholders.
On April 5, the U.S. government surprisingly backed a global initiative to temporarily suspend patent rights on COVID-19 vaccines in order to promote the containment of the pandemic.
Other governments, for instance in Germany, oppose such a move, saying it would be unlikely to turbo-charge global production.